These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35323362)

  • 21. Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.
    Lexchin J
    BMJ Open; 2017 Oct; 7(10):e018372. PubMed ID: 29061631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
    Rawson NSB
    Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review.
    Rocchi A; Chabot I; Glennie J
    Clinicoecon Outcomes Res; 2015; 7():287-98. PubMed ID: 26082654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations.
    Binder L; Ghadban M; Sit C; Barnard K
    Curr Oncol; 2022 Mar; 29(3):1514-1526. PubMed ID: 35323327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011-2017.
    Skedgel C; Wranik D; Hu M
    Pharmacoeconomics; 2018 Apr; 36(4):467-475. PubMed ID: 29353385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs.
    Costa S; Bentley C; Regier DA; McTaggart-Cowan H; Mitton C; Burgess MM; Peacock SJ
    BMC Public Health; 2019 Jul; 19(1):977. PubMed ID: 31331312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada.
    Li YYR; Mai H; Trudeau ME; Mittmann N; Chiasson K; Chan KKW; Cheung MC
    Curr Oncol; 2020 Oct; 27(5):e495-e500. PubMed ID: 33173389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health.
    Balijepalli C; Gullapalli L; Joshy J; Rawson NS
    J Comp Eff Res; 2024 May; 13(5):e230178. PubMed ID: 38567953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans.
    Salek S; Lussier Hoskyn S; Johns JR; Allen N; Sehgal C
    Front Pharmacol; 2019; 10():196. PubMed ID: 30983993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of rarity on Canadian oncology health technology assessment and funding.
    Keech J; Dai WF; Trudeau M; Mercer RE; Naipaul R; Wright FC; Ferguson SE; Darling G; Gavura S; Eisen A; Kouroukis CT; Beca J; Chan KKW
    Int J Technol Assess Health Care; 2020 Aug; ():1-6. PubMed ID: 32779560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).
    Masucci L; Beca J; Sabharwal M; Hoch JS
    Pharmacoecon Open; 2017 Dec; 1(4):255-263. PubMed ID: 29441502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Describing Sources of Uncertainty in Cancer Drug Formulary Priority Setting across Canada.
    Jenei K; Peacock S; Burgess M; Mitton C
    Curr Oncol; 2021 Jul; 28(4):2708-2719. PubMed ID: 34287280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications.
    Salek SM; Lussier Hoskyn S; Johns J; Allen N; Sehgal C
    Front Pharmacol; 2018; 9():1578. PubMed ID: 30833899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of product listing agreements by Canadian provincial drug benefit plans.
    Morgan SG; Friesen MK; Thomson PA; Daw JR
    Healthc Policy; 2013 May; 8(4):45-55. PubMed ID: 23968637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dog's breakfast: prescription drug coverage varies widely across Canada.
    Anis AH; Guh D; Wang Xh
    Med Care; 2001 Apr; 39(4):315-26. PubMed ID: 11329519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021.
    Lau C; Dranitsaris G
    Curr Oncol; 2022 Oct; 29(11):8031-8042. PubMed ID: 36354695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Focused Jurisdictional Scan of Glomerulonephritis Medication Access in Canada: A Program Report.
    Naipaul R; Marques C; Ng J; Barbour S; Lo C; Hildebrand AM; Siu V; Prasad B; Laurin LP; Wazny LD; Armstrong S; Tran J; Sheffield M; Jauhal A; Hladunewich MA
    Can J Kidney Health Dis; 2023; 10():20543581231190227. PubMed ID: 37581108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
    Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W
    BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value assessment of oncology drugs using a weighted criterion-based approach.
    Ezeife DA; Dionne F; Fares AF; Cusano ELR; Fazelzad R; Ng W; Husereau D; Ali F; Sit C; Stein B; Law JH; Le L; Ellis PM; Berry S; Peacock S; Mitton C; Earle CC; Chan KKW; Leighl NB
    Cancer; 2020 Apr; 126(7):1530-1540. PubMed ID: 31860138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.